This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb, Lilly USA, LLC, and Merck & Co.

Collaborative Management of Patients with Gastric Cancer

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center

Steve Malangone, MSN, FNP-C, AOCNP®
University of Arizona Cancer Center

Advanced gastric and esophageal cancers are associated with poor outcomes. However, as knowledge of disease biology improves, treatment options are increasing. Genomic profiling has identified targetable mutations or biomarkers, such as HER2. Immunotherapies such as checkpoint inhibitors may be approved for gastrointestinal malignancies in the very near future. This program provides an overview of clinical trials, new treatment options, as well as practical clinical information regarding diagnosis, staging, monitoring, and managing side effects to treatment, in order to ameliorate clinical confidence and patient outcomes.


Download Podcast

   To claim credit for podcast click here

Download Transcript


Download Slides


Download Slides & Transcripts

   To claim credit for the slides & transcript click here

These CE/CME/CEU accredited activities are jointly provided by

JADPRO Logo    Harborside Press Logo    APSHO Logo    Annenberg Logo
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here